Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389376 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of Silymarin for Chronic Liver Diseases
A Phase 1 study of Hepatitis C and Non-alcoholic Fatty Liver Disease, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 5
- Study locations
NCT00389376: Completed Phase 1 study of Hepatitis C and Non-alcoholic Fatty Liver Disease, sponsored by National Center for Complementary and Integrative Health (NCCIH).
NCT00389376 is a Phase 1 study of Hepatitis C and Non-alcoholic Fatty Liver Disease that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 56 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00389376, a Phase 1 study of Hepatitis C and Non-alcoholic Fatty Liver Disease, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of different dosages of silymarin on subjects with Hepatitis C or Non-Alcoholic Fatty Liver Disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Silymarin
Study Locations (5)
Pennsylvania
- University of Pennsylvania - Philadelphia
- Thomas Jefferson University - Philadelphia
- University of Pittsburgh, Graduate School of Public Health - Pittsburgh
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
What the finished NCT00389376 record still lists
NCT00389376 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00389376 lists 5 locations in 3 states (Pennsylvania, Massachusetts, North Carolina).
Frequently Asked Questions
What is clinical trial NCT00389376 about?
NCT00389376 is a clinical study titled "Phase I Trial of Silymarin for Chronic Liver Diseases". The purpose of this study is to determine the safety and tolerability of different dosages of silymarin on subjects with Hepatitis C or Non-Alcoholic Fatty Liver Disease.
What is the current status of trial NCT00389376?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2006-11. Estimated completion is 2008-02.
What conditions does trial NCT00389376 study?
This clinical trial studies the following conditions: Hepatitis C, Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT00389376?
The interventions under investigation include: Placebo (DRUG), Silymarin (DRUG).
Who is sponsoring clinical trial NCT00389376?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00389376 being conducted?
This trial has 5 study locations across Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00389376's enrollment target sits among peer trials
56 70th of 106 higher than 37 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
COMPLETED · Phase 1
-
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 1
-
Open-Label Hepatic Impairment Study
COMPLETED · Phase 1
-
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
COMPLETED · Phase 1
-
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia